ARTICLE | Clinical News

Aurinia sinks on Phase IIb lupus nephritis results

August 15, 2016 7:00 AM UTC

Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) lost more half its value Monday after reporting data from the Phase IIb AURA-LV study of voclosporin ( LX211) to treat active lupus nephritis (LN). Although one of the study's two doses met AURA-LV's primary endpoint, the company said 12 of 13 deaths in the 265-patient trial were in patients who received voclosporin.

Aurinia fell C$2.85 (55%) to C$2.35 in Toronto and lost $2.28 (56%) to $1.81 on NASDAQ. ...